-- 
Boehringer Says New Study Shows Benefits of BIBF 1120

-- B y   R a j i v   S e k h r i
-- 
2011-09-22T06:09:48Z

-- http://www.bloomberg.com/news/2011-09-22/boehringer-says-new-study-shows-benefits-of-bibf-1120.html
Boehringer Ingelheim said Phase II
clinical trial results for its tyrosine kinase inhibitor (TKI)
BIBF 1120 showed a positive trend in reducing lung function
decline in patients with idiopathic pulmonary fibrosis (IPF),
according to a statement e-mailed today by the company.  To contact the editor responsible for this story:
Rajiv Sekhri at 
 rsekhri1@bloomberg.net  